Wayne Montgomery, J.D., joins iPierian with over twenty years of experience as an intellectual property law attorney in the biopharmaceutical industry. He most recently served as Vice President of Patents at Exelixis. Previously, he served as Vice President of Intellectual Property at Nektar Therapeutics. He held the position of Vice President, Assistant General Counsel & Chief Patent Counsel at Axys Pharmaceuticals prior to its acquisition by Celera, and subsequently Vice President of Intellectual Property at Celera Genomics. Mr. Montgomery began his legal career with Syntex Legal Affairs. Prior to entering the legal profession, he served as a pharmacologist with Syntex Research. He received a J.D. degree from Santa Clara University School of Law and undergraduate degrees in biochemistry and pharmacology from the University of California, Santa Barbara.
iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.
The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gl
|SOURCE iPierian, Inc.|
Copyright©2010 PR Newswire.
All rights reserved